Skip to main content
. 2024 Jul 3;9(28):30945–30953. doi: 10.1021/acsomega.4c03949

Figure 3.

Figure 3

Therapeutic effect of AAV6-iCasp9 vectors and their exosome counterparts in an HCC xenograft model. Graphical representation of tumor regression in vivo after suicide gene therapy with naked AAV6-iCasp9 vectors (A) and Exo-AAV6-iCasp9 vectors (C). Representative images of test animals from different experimental groups 10 days post vector administration with AAV6-iCasp9 vectors (B) and Exo-AAV6-iCasp9 vectors (D). The treated groups AAV6-CAG-iCasp9 (n = 5), AAV6-LP1Kozak-iCasp9 (n = 11), and AAV6-E2F1Birc5Kozak-iCasp9 (n = 7) demonstrated significant tumor regression in comparison to mock-injected animals (n = 5). A similar pattern of tumor regression was also found in animals that received Exo-AAV6-CAG-iCasp9 (n = 11), Exo-AAV6-LP1Kozak-iCasp9 (n = 12), and Exo-AAV6-E2F1Birc5Kozak-iCasp9 (n = 7) vectors when compared to mock-injected animals (n = 10). Two-way ANOVA was performed for statistical analysis. Animals that died or had necrotic tumors were excluded from the analysis. Data are presented as mean ± SD, *p ≤ 0.05; **p ≤ 0.01; and ***p ≤ 0.001 in comparison to mock.